Worldwide standardization of ErbB2 assessment is an important goal not only for obtaining unbiased data on the prevalence of ErbB2-positive breast cancer but also to ensure that patients receive the most appropriate treatment. This evidence concerns the gene ERBB2 and breast cancer.